These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 8585041)
1. Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. Hamamoto T; Kisiel W Thromb Res; 1995 Nov; 80(4):291-7. PubMed ID: 8585041 [TBL] [Abstract][Full Text] [Related]
2. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Hamamoto T; Kisiel W Blood Coagul Fibrinolysis; 1996 Jun; 7(4):470-6. PubMed ID: 8840000 [TBL] [Abstract][Full Text] [Related]
3. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces. Hamamoto T; Yamamoto M; Nordfang O; Petersen JG; Foster DC; Kisiel W J Biol Chem; 1993 Apr; 268(12):8704-10. PubMed ID: 8473315 [TBL] [Abstract][Full Text] [Related]
4. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Enjyoji K; Miyata T; Kamikubo Y; Kato H Biochemistry; 1995 May; 34(17):5725-35. PubMed ID: 7727433 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184 [TBL] [Abstract][Full Text] [Related]
6. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Sprecher CA; Kisiel W; Mathewes S; Foster DC Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3353-7. PubMed ID: 8159751 [TBL] [Abstract][Full Text] [Related]
7. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Mast AE; Broze GJ Blood; 1996 Mar; 87(5):1845-50. PubMed ID: 8634431 [TBL] [Abstract][Full Text] [Related]
8. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor. Lockett JM; Mast AE Biochemistry; 2002 Apr; 41(15):4989-97. PubMed ID: 11939795 [TBL] [Abstract][Full Text] [Related]
9. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716 [TBL] [Abstract][Full Text] [Related]
10. Role of exosite binding modulators in the inhibition of Fxa by TFPI. Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136 [TBL] [Abstract][Full Text] [Related]
11. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. Warshawsky I; Bu G; Mast A; Saffitz JE; Broze GJ; Schwartz AL J Clin Invest; 1995 Apr; 95(4):1773-81. PubMed ID: 7706485 [TBL] [Abstract][Full Text] [Related]
12. TFPI-dependent activities of protein S. Peraramelli S; Rosing J; Hackeng TM Thromb Res; 2012 May; 129 Suppl 2():S23-6. PubMed ID: 22425215 [TBL] [Abstract][Full Text] [Related]
13. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Liu Y; Stack SM; Lakka SS; Khan AJ; Woodley DT; Rao JS; Rao CN Arch Biochem Biophys; 1999 Oct; 370(1):112-8. PubMed ID: 10496984 [TBL] [Abstract][Full Text] [Related]
14. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes. Li A; Chang AC; Peer GT; Wun TC; Taylor FB Thromb Haemost; 2001 May; 85(5):830-6. PubMed ID: 11372676 [TBL] [Abstract][Full Text] [Related]
15. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Cunningham AC; Hasty KA; Enghild JJ; Mast AE Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418 [TBL] [Abstract][Full Text] [Related]
16. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Piro O; Broze GJ Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366 [TBL] [Abstract][Full Text] [Related]
17. Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor. Franssen J; Salemink I; Willems GM; Wun TC; Hemker HC; Lindhout T Biochem J; 1997 Apr; 323 ( Pt 1)(Pt 1):33-7. PubMed ID: 9173898 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of lipoprotein lipase activity by tissue factor pathway inhibitor. Mukherjee M; Kakkar VV Thromb Haemost; 1999 Dec; 82(6):1648-51. PubMed ID: 10613650 [TBL] [Abstract][Full Text] [Related]
19. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease. Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809 [TBL] [Abstract][Full Text] [Related]
20. Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. Lindhout T; Willems G; Blezer R; Hemker HC Biochem J; 1994 Jan; 297 ( Pt 1)(Pt 1):131-6. PubMed ID: 8280090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]